Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34812840.
- Also identified by DOI 10.1001/jamaoncol.2021.6764 and PMC identifier 8611511.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.
Medical subject headings
- COVID-19
- Neoplasms